Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Download PDF Copy

Jan 5 2016

NewsGuard 100/100 Score

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6^th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA. Dr. Karen L. Reckamp, Associate Professor at the City of Hope Comprehensive Cancer Center will present the poster titled "Phase l/ll trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)."

Session Information:
Date: January 6, 2016 12:30-2:30
Location: Encore, Abbey Road and Penny Lane rooms
Poster Number: B21

Source:

Xcovery

Posted in: Drug Trial News | Medical Condition News

Tags: B Cell, Cancer, Cell, Clinical Trial, Kinase, L.L., Lung Cancer, Lungs, Lymphoma, Neuroblastoma, Non-Small Cell Lung Cancer, Oncology, Small Cell Lung Cancer, T-Cell, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

Air pollution linked to head and neck cancer risk

Air pollution linked to head and neck cancer risk

Study shows cannabis as a genotoxic substance with cancer risks

Study shows cannabis as a genotoxic substance with cancer risks

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover mechanism affecting splicing process in retinal cells

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

How different types of bread impact cancer risk

How different types of bread impact cancer risk

MRI-guided SBRT reduces side effects in prostate cancer treatment

MRI-guided SBRT reduces side effects in prostate cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths